RT Journal Article
SR Electronic
T1 Quantitative cone contrast threshold testing in patients with differing pathophysiological mechanisms causing retinal diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.10.20228619
DO 10.1101/2020.11.10.20228619
A1 Kayla M. White
A1 Caroline Frambach
A1 John Doan
A1 Urmi V. Mehta
A1 Itamar Livnat
A1 Clara Yuh
A1 Anton M. Palma
A1 Kimberly A. Jameson
A1 M. Cristina Kenney
A1 Mitul C. Mehta
A1 Chantal J. Boisvert
A1 Wade R. Crow
A1 Andrew W. Browne
YR 2020
UL http://medrxiv.org/content/early/2020/11/13/2020.11.10.20228619.abstract
AB Purpose Cone contrast threshold testing (CCT) provides quantitative measurements of color and contrast function to reveal changes in vision quality that is not a standard endpoint in clinical trials. We utilize CCT to measure visual function in patients with multiple sclerosis (MS), age-related macular degeneration (AMD), epiretinal membrane (ERM), and retinal vein occlusion (RVO).Methods Retrospective data was gathered from 268 patients of the Gavin Herbert Eye Institute. Subjects included 17 patients with MS, 45 patients with AMD, 41 patients with ERM, 11 patients with RVO, and 123 age and visual acuity-matched healthy controls. Patients underwent the primary measurement outcome, CCT testing, as well as Sloan visual acuity test and spectral domain optical coherence tomography during normal care.Results Color and contrast deficits were present in MS patients regardless of history of optic neuritis. AMD with intermediate or worse disease demonstrated reduced CCT scores. All 3 stages of ERM demonstrated cone contrast deficits. Despite restoration of visual acuity, RVO-affected eyes demonstrated poorer CCT performance than unaffected fellow eyes.Conclusions CCT demonstrates color and contrast deficits for multiple retinal diseases with differing pathophysiology. Further prospective studies of CCT in other disease states and with larger samples sizes is warranted.Brief Summary Statement In a retrospective analysis of 268 adults, cone contrast threshold testing (CCT) demonstrates patterns of visual function deficits in multiple sclerosis and age-related macular degeneration and similar declines in epiretinal membranes and retinal vein occlusion beyond standard visual acuity. Across all disease states, color and contrast vision were negatively impacted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, through RPB unrestricted grant to UCI Department of Ophthalmology ICTS KL2, grant numbers: KL2 TR001416 and UL1 TR001414 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of California Irvine IRB aproval HS#2019-5254 and HS#2019-5411All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable upon request